Comparison of salbutamol given by intermittent positive-pressure breathing and pressure-packed aerosol in chronic asthma

PB ANDERSON, A GOUDE, MD PEAKE

From the Department of Respiratory Diseases, Lodge Moor Hospital, Sheffield

ABSTRACT A double-blind crossover study was performed to compare 4.8 mg salbutamol given by pressure-packed aerosol and intermittent positive-pressure breathing nebulisation in chronic asthmatic patients. The two delivery techniques produced similar changes in respiratory function and pulse rates. Given equal effect, a high-dose pressure-packed aerosol would have advantages in cost and convenience over nebulisation techniques.

Interest has grown recently in the various methods available for the delivery of bronchodilators to asthmatics. Comparisons have been made between intravenous and nebulised bronchodilators in acute asthma^{1,2} and between intermittent positive-pressure breathing and non-pressurised nebulisation.³ Salbutamol given by pressure-packed aerosol and by nebulisation has been investigated in both acute⁴ and chronic⁵ asthma and also in chronic bronchitis.⁶ The doses of bronchodilator used in these studies of different inhalational delivery techniques, however, have differed greatly, 200 or 400 µg salbutamol by pressure-packed aerosol being compared with 5 or 10 mg by nebuliser. More nearly equivalent doses given by the two methods have not been compared.

The calculation of equivalent doses is problematical because of variation in the amount of drug deposited in the respiratory tract by the systems. About 10% of a dose delivered from a pressure-packed aerosol is deposited in the lung,⁷ and it has been calculated that on average 25% of a dose given by intermittent positive-pressure breathing is available to the patient and about 12.5% of the dose is absorbed.⁸ We have investigated the effects of equal doses of salbutamol given by pressure-packed aerosol and intermittent positive-pressure breathing in asthmatics in a stable state; while accepting that it is probably not possible to ensure that identical quantities reach the lung, we believe that a reasonable approximation was achieved, to judge by present information. A triggered intermittent positive-

pressure breathing device was chosen to drive the nebuliser so that the amount of drug reaching the patient could be more closely controlled, nebulisation not continuing during the patient's expiratory phase.

Methods

We investigated 10 patients with chronic asthma in a stable state. The diagnosis of asthma was made on clinical grounds and the subjects had previously been shown to have appreciable potential for reversal of their asthma, with an improvement of over 15% in the forced expiratory volume in one second (FEV₁) after 5 mg salbutamol by nebulisation but a poor response to a dose of 200 µg salbutamol from a pressure-packed aerosol. The mean improvement 20 minutes after 200 µg salbutamol was 8.8% (SD 4.2). Their mean age was 51.7 years (SD 8.72). One patient was taking inhaled corticosteroids and prednisolone, seven inhaled corticosteroids and intramuscular triamcinolone, and two oral prednisolone. All subjects gave informed consent.

Each patient received two treatment regimens in a randomised double-blind crossover study. The treatments were given on different days, starting at the same time of the day. The two regimens were salbutamol from a pressure-packed aerosol followed by placebo by intermittent positive-pressure breathing (Harlow Mk2, British Oxygen Co Ltd IPPB device driven by a compressed air cylinder, and a Sandoz nebuliser) and placebo pressure-packed aerosol followed by salbutamol respirator solution by intermittent positive-pressure breathing. The patients were all familiar with the delivery sys-

tems and investigatory techniques and had not had bronchodilators for six hours.

The solution was nebulised over 12–15 minutes. To take into account the possibility of differences in bronchodilator action in the later stages of nebulisation due to better drug penetration because of previously achieved bronchodilatation, the dose from the pressure-packed aerosol was also fractionated. The total dose from the pressure-packed aerosol was given over 10 minutes.

The pressure-packed aerosol used was a special high-dose salbutamol inhaler delivering 400 µg/puff. Two puffs were given at two-minute intervals until a total of 12 puffs (4.8 mg) had been given. Similarly, 4.8 mg, or the equivalent volume of placebo, were given by intermittent positive-pressure breathing, the total volume being made up to 2 ml with 0.9% saline.

The experimental design was as follows. Baseline measurements of FEV₁ and forced vital capacity (FVC) were made (Monaghan M403, Sandoz Products Ltd), the best of three attempts being taken. Thoracic gas volume and airways resistance were estimated by whole-body plethysmography (PK Morgan Ltd) and the resting pulse rate was counted. The subject then took two puffs from the study pressure-packed aerosol, a slow expiration to residual volume being followed by a 10-second breath hold after a maximal inspiration. Six double puffs were taken at two-minute intervals, a single measurement of FEV₁ and FVC being taken immediately before the next inhalation. Spirometry and counting of the pulse rate were repeated at 15 minutes and at 30 minutes. At 45 minutes pulse rate, spirometry, and whole-body plethysmography were all repeated.

At 60 minutes from the beginning of the procedure the subject received the study solution nebulised by intermittent positive-pressure breathing. Spirometry was repeated at two-minute intervals until all the solution had been nebulised. At 75 minutes and 90 minutes the pulse rate was measured and spirometry carried out and finally at 105 minutes spirometry, pulse rate, and whole-body plethysmography were repeated. An identical protocol was followed on the second investigation day.

The results for FEV₁, FVC, thoracic gas volume, and pulse rate were analysed by paired *t* test. Specific airway conductance (sGaw) was analysed after transformation to log_e sGaw by paired *t* test as the distribution of sGaw is skewed.⁹

Results

One patient's baselines were found to vary by more than 15% after the code had been broken and his

results were excluded from analysis. The following analysis is therefore based on nine subjects.

SPIROMETRY

The changes in FEV₁ with time for the two treatments (active inhaler followed by placebo nebulisation and placebo inhaler followed by active nebulisation) are shown in figure 1. The baseline (time 0) on the two days did not vary significantly (*p* > 0.3).

The active pressure-packed aerosol produced a significant improvement in FEV₁ at 45 minutes compared with baseline (*p* < 0.03) but the placebo produced no significant change over the same period (*p* > 0.3). A significantly greater percentage change in FEV₁ had occurred by 45 minutes after the active than the placebo aerosol (*p* < 0.035). There was no change in FEV₁ between 45 and 60 minutes after the active aerosol (*p* > 0.7), nor did the placebo nebulisation produce further bronchodilatation (*p* > 0.4).

After the placebo pressure-packed aerosol the FEV₁ at 45 minutes did not differ from baseline (*p* > 0.3) nor did the 60-minutes value differ from that at 45 minutes (*p* > 0.4). Nebulisation of active solution was followed by a highly significant increase in FEV₁ (*p* < 0.001). For the group, however, there was no significant difference in the percentage change in FEV₁ after salbutamol from a pressure-packed aerosol and salbutamol by intermittent positive-pressure breathing nebulisation (*p* > 0.4).

The changes in FVC are shown in figure 2 and show a pattern similar to the FEV₁ changes. The two delivery systems resulted in an identical rate of change in spirometry values. Within the group three patients tended to respond better to the nebuliser and two to the pressure-packed aerosol. The numbers are too small for further analysis but there was no clear relation to FEV₁ or other factor.

WHOLE-BODY PLETHYSMOGRAPHY

sGaw Log_e sGaw and other plethysmographic results are shown in table 1. The active pressure-packed aerosol produced a highly significant improvement in log_e sGaw (*p* < 0.002) and nebulised placebo solution did not result in a further change (*p* > 0.7). Placebo pressure-packed aerosol did not result in a significant change (*p* > 0.05) but nebulised salbutamol caused a significant improvement (*p* < 0.04). The baseline values of log_e sGaw on the two treatment days were significantly different (*p* < 0.025) but the percentage change after the active pressure-packed aerosol was highly significantly greater than after placebo pressure-packed aerosol (*p* < 0.0015). However, log_e sGaw before active pressure-packed aerosol and active nebuliser solution (0 minutes and

Fig 1 Mean FEV₁ after salbutamol given by pressure-packed aerosol (PPA) and intermittent positive-pressure breathing (IPPB).

Fig 2 Mean FVC after salbutamol given by pressure-packed aerosol (PPA) and intermittent positive-pressure breathing (IPPB).

Table 1 Changes in $\log_e$ sGaw and thoracic gas volume (TGV) on the two treatment schedules

Time (min)	Active PPA		Placebo IPPB		Placebo PPA		Active IPPB	
	0	45	105		0	45	105	
$\log_e$ sGaw								
Mean	-3.146	-2.512	-2.464		-2.922	-3.084	-2.728	
(sGaw)	(0.043)	(0.081)	(0.085)		(0.054)	(0.046)	(0.065)	
SD	0.376	0.476	0.579		0.421	0.480	0.652	
TGV (litres)								
Mean	5.11	4.6	4.51		5.35	5.66	4.42	
SD	1.73	1.61	1.38		2.12	2.45	1.25	

PPA—pressure-packed aerosol; IPPB—intermittent positive-pressure breathing.

Table 2 Changes in pulse rate on the two treatment schedules

Time (min)	Active PPA				Placebo IPPB				Placebo PPA				Active IPPB			
	0	15	30	45	75	90	105		0	15	30	45	75	90	105	
Pulse rate																
Mean	96	112	108	111	108	107	109		92	101	97	97	104	106	104	
SD	17	21	18	19	22	16	19		21	21	20	20	19	19	20	

PPA—pressure-packed aerosol; IPPB—intermittent positive-pressure breathing.

45 minutes respectively) did not differ ($p > 0.5$) and a greater percentage change in $\log_e$ sGaw occurred after salbutamol from a pressure-packed aerosol than after intermittent positive-pressure breathing nebulisation ($p < 0.05$).

Thoracic gas volume Baseline thoracic gas volume was similar on the two treatment days ($p > 0.4$). After the active pressure-packed aerosol there was a significant fall in thoracic gas volume ($p < 0.05$), which did not occur with placebo ($p > 0.2$). The placebo nebuliser solution did not result in a further change ($p > 0.5$) but nebulised salbutamol did cause a fall ($p < 0.02$). Before the two active treatments thoracic gas volume was similar ($p = 0.2$) and the percentage change produced was not significantly different ($p > 0.1$).

Pulse rates The changes in pulse rate are shown in table 2. There was a statistically significant increase in pulse rate at all times of recording after 4.8 mg salbutamol delivered by pressure-packed aerosol and nebuliser. The pulse rate did not change significantly after use of the placebo pressure-packed aerosol or nebuliser. The percentage change was similar for the two delivery methods ($p = 0.1$).

Side effects One patient developed tremor when receiving salbutamol from both the nebuliser and the pressure-packed aerosol, one when receiving nebulised drug, and one after the pressure-packed aerosol.

Discussion

A 4.8-mg dose of salbutamol given by pressure-packed aerosol has been shown to be just as effective in terms of improvement in FEV₁ and FVC as the same dose given by intermittent positive-pressure breathing nebulisation in a group of chronic asthmatic patients with a relatively poor response to standard 200- μ g doses. Changes in thoracic gas volume and pulse rate did not differ significantly with the two delivery techniques, although the pressure-packed aerosol produced a significantly larger change in sGaw than did nebulisation. That a roughly equivalent dose of bronchodilator given by the two methods produced similar overall changes in respiratory function indicates that disparity in dosage has been the important factor in determining the outcome of previous comparative studies of pressure-packed aerosol and intermittent positive-pressure breathing⁴⁻⁶ and not the delivery technique itself.

Although not yet of proved value, outpatient and domiciliary nebulisation of bronchodilators is currently in vogue for chronic airflow obstruction.^{10 11} The use of cylinder or compressor-driven nebulisers, whether or not they are of the intermittent positive-pressure breathing type, by patients at home has financial implications. Firstly, the units originally available were in the main intermittent positive-pressure breathing devices and therefore expensive. Less expensive devices not using intermittent positive-pressure breathing are now avail-

able but £60–100 is required for each unit. In some areas hospitals provide the equipment, in others the patient buys his own machine. Secondly, arrangements for regular servicing and safety checks have to be made. If appreciable numbers of patients receive such treatment, the financial commitment in terms of capital investment, drugs, and revenue consequences, including technicians' time or service contracts, could become considerable.

We have shown that a high dose of salbutamol from a pressure-packed aerosol will produce worthwhile improvement in respiratory function equal to that achieved by the same dose given by intermittent positive-pressure breathing in severe chronic asthma. We have not found side effects or tachycardia to be unacceptable when compared with those produced by the established technique of giving high doses by nebulisation. Were a high-dose inhaler available, it would be of advantage to those who do not respond optimally to current pressure-packed aerosols. It might be argued that a high-dose pressure-packed aerosol could be abused but a respirator solution and nebuliser unit for domiciliary use have the same potential.

Whether regular high doses of bronchodilator are of benefit in chronic airflow obstruction remains to be determined; but the use of a high-dose pressure-packed aerosol rather than intermittent positive-pressure breathing or other forms of nebulisation would have clear advantages in terms of cost, convenience, and simplicity.

We thank Dr LA Philips for advice and Allen and Hanbury Ltd for the material used in the study.

References

- ¹ Bloomfield P, Carmichael J, Petrie JR, Jewell NP, Crompton GK. Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma. *Br Med J* 1979;i:848–50.
- ² Williams S, Seaton A. Intravenous or inhaled salbutamol in severe acute asthma? *Thorax* 1977;32:555–8.
- ³ Campbell IA, Hill A, Middleton H, Momen M, Prescott RJ. Intermittent positive pressure breathing. *Br Med J* 1978;i:1186.
- ⁴ Cayton RM, Webber B, Paterson JW, Clark TJH. A comparison of salbutamol by pressure packed aerosol or nebulisation via IPPB in acute asthma. *Br J Dis Chest* 1978;72:222–4.
- ⁵ Choo-Kang YFJ, Grant IWB. Comparison of two methods of administering bronchodilator aerosol to asthmatic patients. *Br Med J* 1975;iii:119–20.
- ⁶ Berend N, Webster J, Marlin GE. Salbutamol by pressure packed aerosol and by intermittent positive pressure ventilation in chronic obstructive bronchitis. *Br J Dis Chest* 1978;72:112–4.
- ⁷ Newman SP, Pavia D, Sheahan NF, Moren F, Clarke SW. Deposition of pressurised aerosols in the lung using radio labelled particles. *Thorax* 1980;35:234.
- ⁸ Shenfield GM, Evans ME, Walker SR, Paterson JW. The fate of nebulised salbutamol administered by intermittent positive pressure respiration to asthmatic patients. *Am Rev Respir Dis* 1973;108:501–5.
- ⁹ Guyatt AR, Alpers JH. Factors affecting airways conductance: a study affecting 752 working men. *J Appl Physiol* 1968;24:310–6.
- ¹⁰ Connellan SJ, Wilson RSE. The use of domiciliary nebulised salbutamol in the treatment of severe emphysema. *Br J Clin Pract* 1979;3:135–6.
- ¹¹ Wilson RSE, Connellan SJ. Domiciliary nebulised salbutamol solution in severe chronic airways obstruction. *Thorax* 1980;35:873–6.